This is the authors' abstract. We don't add key points for this paper.
Among patients with NSCLC included in a longitudinal database of clinical data linked to CGP results from routine care, exploratory analyses replicated previously described associations between clinical and genomic characteristics, between driver mutations and response to targeted therapy, and between TMB and response to immunotherapy. These findings demonstrate the feasibility of creating a clinicogenomic database derived from routine clinical experience and provide support for further research and discovery evaluating this approach in oncology.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Singal et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: